- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02715882
Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer
February 8, 2017 updated by: BioLab 612 LLC
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Moscow, Russian Federation
- Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written Patient Informed Consent for participation in the study
- Men and women in the age above 18 years
- Patients with confirmed diagnosis of colorectal cancer, indication to scheduled surgery for primary tumor removal
- Should not have any previous anticancer therapy
- Patient's life expectancy more than 3 months
- ECOG performance status 0-1
Adequate hepatic and renal function:
- Total bilirubin ≤1.5 upper limit of normal (ULN)),
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN, regardless of the presence of liver metastases,
- Creatinine ≤2 x ULN
Adequate cardiac function including:
- LVEF ≥45 by echocardiogram (ECHO) or multi gated acquisition scan,
- 12-lead electrocardiogram (ECG) with normal tracing or non-clinically significant changes that do not require medical intervention,
- QTcB interval QT (QTc by Bazett's formula) < 470 msec and no history of Torsades des Pointes or other symptomatic QTcB abnormality,
- Absence of orthostatic hypotonia
- Negative testing for serological markers of HIV-infection, viral hepatitis В and С, syphilis
- Content to use barrier contraception methods by male/female patient and his/her partner in the study period
Exclusion Criteria:
- Inability to obtain written Informеd consent for participation in the study
History of cardiovascular abnormalities including any conditions stated below:
- Myocardial infarction/stroke for the last 6 months,
- Stable abnormalities in regional contractility,
- Cardiac failure (NYHA functional class III-IV),
- Confirmed cardiomyopathy,
Clinically significant arrhythmias including any conditions stated below:
- QT prolongation syndrome,
- History of II or III-degree AV-block,
- Bradycardia (HR < 50 beats per min.) or tachycardia (HR >100 beats per min.)
Blood pressure abnormalities:
- 2 degree uncontrolled arterial hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 105 mm Hg),
- Hypotension (systolic blood pressure < 90 mm Hg)
- History of severe allergic, systemic and other oncologic diseases
- Decompensated diabetes mellitus with glycolated hemoglobin level (HbA1c) > 7%
- Administration of drug products with evident effect on immune system for previous 3 months prior screening (including corticosteroids. Remark: Topical agents (e.g. for rash treatment), inhalation aerosols (e.g. for treatment of broncho-obstructive diseases), eye drops and agents for local administration (e.g. to joint cavity) is allowed
- Participation in other clinical studies or administration of study products for 30 days prior screening, or persisting adverse reactions of the study product
- Patients that have not taken CBLB502
- Patients with hypersensitivity/allergy to CBLB502 or excipients of the drug product; NSAID (including ibuprofen)
- Pregnant or lactating women
- History of salmonellosis
- Body mass > 88 kg; no obesity which means BMI in the range 18.5-25 kg/m2 for women and 22-27 kg/m2 for men
- Men and women of childbearing age which do agree to use double contraception method, oral contraception or abstain from sex contacts throughout the study
- Alcohol abuse, drug abuse and any other medical, psychological and social reasons which may, in accordance with the investigator, affect patient's participation in the study, may prevent adequate assessment of the study results
- Any conditions which are unstable or may endanger patient's safety and/or affect his/her adherence to the investigator instruction
- Any patient is not able or willing to cooperate with the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 injection of CBLB502 0.35 μg/kg
One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
|
Other Names:
Other Names:
|
Experimental: 1 injection of CBLB502 0.45 μg/kg
One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
|
Other Names:
Other Names:
|
Experimental: 2 injections of CBLB502 0.35 μg/kg
Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
|
Other Names:
Other Names:
|
Experimental: 2 injections of CBLB502 0.45 μg/kg
Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability evaluation as measured by adverse events and assessed as changes in vital signs and clinical laboratory measurements, physical examination findings and ECG readings
Time Frame: Baseline to up to 14 days after the drug administration
|
Baseline to up to 14 days after the drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assessment of immune cells change in tumor by H&E and ICH staining
Time Frame: On Day 7 (Surgery day) after the drug administration
|
On Day 7 (Surgery day) after the drug administration
|
Determination of levels of cytokine IL-6 in blood by multiplex assays
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Determination of levels of cytokine IL-8 in blood by multiplex assays
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Determination of levels of cytokine IL-10 in blood by multiplex assays
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Determination of levels of cytokine G-CSF in blood by multiplex assays
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Determination of levels of cytokine TNFа in blood by multiplex assays
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Specific T-cell responses measured by ELIspot
Time Frame: Baseline to up to 14 days after the drug administration
|
Baseline to up to 14 days after the drug administration
|
Antibody titer to CBLB502 as measured by ELISA
Time Frame: Baseline and on day 14 after the drug administration
|
Baseline and on day 14 after the drug administration
|
Blood leukocytes by FACS
Time Frame: Baseline to up to 7 days after the drug administration
|
Baseline to up to 7 days after the drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sergei I. Achkasov, MD PhD, Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation
- Principal Investigator: Nikolay V. Kislov, MD PhD, Federal State Institution of Health of the Yaroslav Region "Regional Clinical Oncology Hospital"
- Principal Investigator: Sergei V. Odintcov, MD PhD, Federal State Budgetary Institution "Central Clinical Hospital with polyclinic" Department of Presidential Affairs of the Russian Federation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
February 1, 2017
Study Completion (Anticipated)
December 31, 2017
Study Registration Dates
First Submitted
March 17, 2016
First Submitted That Met QC Criteria
March 21, 2016
First Posted (Estimate)
March 22, 2016
Study Record Updates
Last Update Posted (Estimate)
February 9, 2017
Last Update Submitted That Met QC Criteria
February 8, 2017
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BL612-CBLB502
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States